Home > Healthcare > Medical Devices > Therapeutic Devices > Bone Graft Substitutes Market

Bone Graft Substitutes Market Trends

Report ID: GMI7993
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Bone Graft Substitutes Market Trends

The prevalence of sports injuries along with athletes worldwide undergoing procedures involving bone graft substitutes to expedite their recovery and regain optimal functions are other factors driving the industry growth. As sports are continuing to evolve and turn more competitive, the demand for several substitutes is steadily increasing. Medical professionals are actively utilizing and researching substitutes to address the specific needs of athletes for ensuring they receive the best possible treatment.

Medical researchers and manufacturers are continually developing and refining substitutes to cater to the evolving requirements of athletes to transform the treatment and rehabilitation of sports-related injuries. For instance, the National SAFE KIDS Campaign and the American Academy of Pediatrics reported that over 3.5 million children aged 14 years and under sustain injuries annually from sports and recreational activities. Such incidents are highlighting the potential demand for advanced treatments like bone graft substitutes in pediatric orthopedic care.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global bone graft substitutes market was valued at over USD 3 billion in 2023 and is estimated to expand at 6.6% CAGR from 2024 to 2032 due to the rising incidence of orthopedic conditions worldwide.

The allograft segment in the bone graft substitutes market is poised to expand at 6.4% CAGR from 2024 to 2032, fueled by wide utilization in orthopedic procedures particularly for their compatibility and effectiveness in promoting bone regeneration.

North America Bone Graft Substituents Market is expected to record 6.1% CAGR through 2032 due to the increasing preference for minimally invasive surgeries and rapid advancements in medical technology.

AlloSource, Baxter International Inc., DePuy Synthes (Johnson & Johnson Inc.), Geistlich Pharma AG, Medtronic plc, NuVasive, Inc., Orthofix US LLC., OST Laboratories, Smith + Nephew, Stryker Corporation and Zimmer Biomet Holdings, Inc.